Document is current

Article History

Received: 18 February 2024

Accepted: 31 July 2024

First Online: 3 August 2024

Declarations

:

: Institutional Review Board Statement: The study was performed in accordance with the Declaration of Helsinki. The protocol was registered with the identifier NCT03220230 (, last accessed May 27, 2021) and approved by local ethics committees for each recruiting hospital: Comite Etico Cientifico Av. Salvador 364, Servicio de Salud Metropolitano Oriente Providencia, SANTIAGO, RM 7500922 CHILE, Comite de Etica Hospital Clinico Universidad de Chile Avenida Santos Dumont 999 Santiago, RM 8380456 CHILE, Comite Etico Cientifico. Servicio de Salud Concepcion San Martin 1436 Concepcion, REGION DEL BIO BIO 4070038 CHILE. Informed Consent Statement: All patients provided informed consent for access to clinical, demographic, and pathology information as well as to available FFPE tumor tissue. Strategies to protect their identity and privacy included anonymization procedures and a unique eight-digit identifier. Patients received no treatment as part of this study.

: Not applicable.

: GS, AB, RA, RAC, MF, LR, DA, RL, JC and PP were Pfizer Chile employees. HF, EDN, DNN, GPB, MGA, CF, TFB, JF, MA, SC, OA, MLS, GR, CS, KM and SR received a grant and non-financial support for to perform this work for CEMP Pfizer Chile. Outside this work, HF discloses personal fees and non- financial support from Pfizer and BMS and non-financial support from AstraZeneca and Roche. RA declares honoraria for conferences, advisory boards, and educational activities from Roche, grants, and support for scientific research from Illumina, Pfizer, Roche & Thermo Fisher Scientific, and honoraria for conferences from Thermo Fisher Scientific, Janssen & Tecnofarma. The other authors declare that they have no competing interests. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.